Physician profile
Uyen-Thi T Cao
NPI 1639100555
$9,306.19
in general payments reported to CMS, 2019-2025
27 companies · $2,942 in 2025
The $2,942 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $255 · 2021: $879 · 2022: $1,241 · 2023: $1,430 · 2024: $1,251 · 2025: $2,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,623.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $2,369.68 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $1,165.23 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.96 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $553.01 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Alexion Pharmaceuticals, INC. | $540.71 | 2022-2025 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals Lp | $527.36 | 2019-2023 | Lokelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.37 | 2019-2025 | Xifaxan |
| Csl Behring | $463.24 | 2019-2025 | Kcentra |
| Abbvie INC. | $357.26 | 2021-2025 | |
| Shionogi INC | $347.73 | 2022-2025 | Fetroja |
| Pfizer INC. | $327.55 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $311.11 | 2023-2025 | Rebyota |
| Astellas Pharma US INC | $298.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $295.12 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $159.90 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $115.02 | 2022-2023 | Veltassa |
| Paratek Pharmaceuticals, INC. | $86.95 | 2019-2024 | Nuzyra |
| Vertex Pharmaceuticals Incorporated | $62.31 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.97 | 2025 | Lifevest |
| Gilead Sciences, INC. | $47.11 | 2021 | |
| Mylan Specialty L.P. | $45.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.78 | 2019 | |
| Aimmune Therapeutics, INC. | $32.17 | 2025 | Vowst |
| Insmed, INC. | $26.91 | 2023 | Arikayce |
| Eusa Pharma (US) LLC | $19.16 | 2019 | |
| Melinta Therapeutics, LLC | $15.22 | 2025 | Rezzayo |
| Cumberland Pharmaceuticals, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uyen-Thi Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.